[Hypotensive effect and characteristics of the effect on the central hemodynamics of the delayed-action form of diltiazem (Dilren) in patients with hypertension].
Calcium antagonist dilren in a short course was given to 11 hypertensive subjects (AH stage II). A clinical response in the majority of the patients was associated with a decline in systolic, mean arterial and resting diastolic pressure (by 8.1, 7.8 and 11.5%, respectively). In orthostasis and under isometric loading dynamic values of arterial pressure tended to lowering, especially diastolic (by 6.7 and 8.3%, respectively). Reduced pressure resulted from a significant reduction in the total peripheral resistance (by 19.8% at rest, in orthostasis by 10%, in isometric load by 26.1%). Minute blood volume increased because of a rise in stroke output. Dilren is recommended in a standard dose 300 mg/day in mild hypertension and in an individual dose 600 mg/day in moderate disease.
Pshenitsin
A I
AI
Glotov
M N
MN
Mazur
N A
NA
D000328:Adult; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D004110:Diltiazem / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged
D000959:Antihypertensive Agents; D003692:Delayed-Action Preparations; D004110:Diltiazem
Otsenka gipotenzivnogo éffekta i osobennosteĭ vliianiia na tsentral'nuiu gemodinamiku retardirovannoĭ formy diltiazema (dilrena) u bol'nykh gipertonicheskoĭ bolezn'iu.